Rational design of a live-attenuated eastern equine encephalitis virus vaccine through informed mutation of virulence determinants.
Animals
Antibodies, Neutralizing
Cell Line
Cricetinae
Encephalitis Virus, Eastern Equine
/ genetics
Encephalomyelitis, Eastern Equine
/ veterinary
Female
Genetic Engineering
/ methods
Horses
Mice
Mutation
North America
Research Design
Vaccines, Attenuated
/ biosynthesis
Viral Vaccines
/ biosynthesis
Virulence
Virulence Factors
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
12
09
2018
accepted:
15
01
2019
revised:
22
02
2019
pubmed:
12
2
2019
medline:
11
4
2019
entrez:
12
2
2019
Statut:
epublish
Résumé
Live attenuated vaccines (LAVs), if sufficiently safe, provide the most potent and durable anti-pathogen responses in vaccinees with single immunizations commonly yielding lifelong immunity. Historically, viral LAVs were derived by blind passage of virulent strains in cultured cells resulting in adaptation to culture and a loss of fitness and disease-causing potential in vivo. Mutations associated with these phenomena have been identified but rarely have specific attenuation mechanisms been ascribed, thereby limiting understanding of the attenuating characteristics of the LAV strain and applicability of the attenuation mechanism to other vaccines. Furthermore, the attenuated phenotype is often associated with single nucleotide changes in the viral genome, which can easily revert to the virulent sequence during replication in animals. Here, we have used a rational approach to attenuation of eastern equine encephalitis virus (EEEV), a mosquito-transmitted alphavirus that is among the most acutely human-virulent viruses endemic to North America and has potential for use as an aerosolized bioweapon. Currently, there is no licensed antiviral therapy or vaccine for this virus. Four virulence loci in the EEEV genome were identified and were mutated individually and in combination to abrogate virulence and to resist reversion. The resultant viruses were tested for virulence in mice to examine the degree of attenuation and efficacy was tested by subcutaneous or aerosol challenge with wild type EEEV. Importantly, all viruses containing three or more mutations were avirulent after intracerebral infection of mice, indicating a very high degree of attenuation. All vaccines protected from subcutaneous EEEV challenge while a single vaccine with three mutations provided reproducible, near-complete protection against aerosol challenge. These results suggest that informed mutation of virulence determinants is a productive strategy for production of LAVs even with highly virulent viruses such as EEEV. Furthermore, these results can be directly applied to mutation of analogous virulence loci to create LAVs from other viruses.
Identifiants
pubmed: 30742691
doi: 10.1371/journal.ppat.1007584
pii: PPATHOGENS-D-18-01790
pmc: PMC6386422
doi:
Substances chimiques
Antibodies, Neutralizing
0
Vaccines, Attenuated
0
Viral Vaccines
0
Virulence Factors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007584Subventions
Organisme : NIAID NIH HHS
ID : R01 AI095436
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI132909
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI111115
Pays : United States
Organisme : NIH HHS
ID : S10 OD016368
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist
Références
Immunology. 2011 Apr;132(4):466-74
pubmed: 21320124
J Virol. 2007 Apr;81(8):3866-76
pubmed: 17267491
J Virol. 2010 May;84(9):4158-71
pubmed: 20147401
J Virol. 2008 Nov;82(21):10634-46
pubmed: 18768986
JAMA. 1965 Nov 22;194(8):872-6
pubmed: 5321495
Vaccine. 2012 Nov 26;30(50):7271-7
pubmed: 23031498
J Virol. 2008 May;82(10):4920-30
pubmed: 18353963
J Exp Med. 2008 Dec 22;205(13):3119-31
pubmed: 19047440
Emerg Infect Dis. 2013 Feb;19(2):194-201; quiz 352
pubmed: 23343480
Nat Med. 2003 Sep;9(9):1131-7
pubmed: 12925846
J Virol. 2008 Jul;82(14):6972-83
pubmed: 18480443
Vaccine. 2010 May 7;28(21):3635-41
pubmed: 20226891
J Virol. 2008 Jun;82(12):6024-33
pubmed: 18400851
J Virol. 2013 Aug;87(15):8582-90
pubmed: 23720725
Am J Trop Med Hyg. 1970 Jan;19(1):119-22
pubmed: 5417610
J Virol. 2017 Jun 26;91(14):
pubmed: 28468884
J Virol. 2009 Oct;83(19):10036-47
pubmed: 19641001
N Engl J Med. 1997 Jun 26;336(26):1867-74
pubmed: 9197215
Vaccine. 2016 Jun 3;34(26):2976-2981
pubmed: 27026149
Nat Immunol. 2009 Jan;10(1):116-125
pubmed: 19029902
Virology. 1996 Oct 1;224(1):73-83
pubmed: 8862401
J Virol. 2014 Feb;88(4):2035-46
pubmed: 24307590
J Gen Virol. 2010 Jun;91(Pt 6):1450-60
pubmed: 20147516
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16026-31
pubmed: 21896745
Virology. 2016 Sep;496:147-165
pubmed: 27318152
J Virol. 2007 Apr;81(7):3563-73
pubmed: 17215278
J Gen Virol. 1986 Apr;67 ( Pt 4):631-7
pubmed: 3958694
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2):49-55
pubmed: 11425162
Science. 2014 Feb 14;343(6172):783-7
pubmed: 24482115
PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004167
pubmed: 26495991
J Infect Dis. 2014 Feb 1;209(3):334-44
pubmed: 24141982
PLoS Pathog. 2016 Jul 27;12(7):e1005786
pubmed: 27463517
J Travel Med. 2016 Jul 04;23(5):
pubmed: 27378369
Clin Infect Dis. 2014 Feb;58(3):e44-100
pubmed: 24311479
Expert Rev Vaccines. 2014 Dec;13(12):1423-5
pubmed: 25073901
J Immunol. 2006 Apr 1;176(7):4343-51
pubmed: 16547272
J Exp Med. 1937 May 31;65(6):767-86
pubmed: 19870633
Virology. 2015 May;479-480:379-92
pubmed: 25864107
Clin Vaccine Immunol. 2017 Jan 5;24(1):
pubmed: 27847366
Am J Trop Med Hyg. 1967 Nov;16(6):762-8
pubmed: 6066224
Biologicals. 1993 Dec;21(4):357-63
pubmed: 8024751
J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9
pubmed: 18419392
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S58-61
pubmed: 15876927
J Virol. 2007 Mar;81(5):2472-84
pubmed: 17108023
J Virol. 1998 Sep;72(9):7357-66
pubmed: 9696832
J Pediatr. 2004 Feb;144(2):184-90
pubmed: 14760258
Nucleic Acids Res. 1996 Apr 15;24(8):1574-5
pubmed: 8628694
Nat Microbiol. 2019 Jan;4(1):187-197
pubmed: 30455470
J Virol. 2007 Dec;81(24):13552-65
pubmed: 17913819
J Virol. 1989 Mar;63(3):1338-44
pubmed: 2536836
Bull World Health Organ. 1981;59(6):895-900
pubmed: 6978196
Vaccine. 1986 Sep;4(3):157-62
pubmed: 3020820
Eur J Immunol. 2010 May;40(5):1315-27
pubmed: 20213733
Vaccine. 1996 Mar;14(4):337-43
pubmed: 8744562
Nature. 2014 Feb 13;506(7487):245-8
pubmed: 24352241